This content is machine translated Prostate Cancer What is the effect of enzalutamide before chemotherapy? Enzalutamide (Xtandi®) prolongs survival in men whose metastatic castration-resistant prostate cancer is progressive after chemotherapy. But is the oral androgen receptor pathway inhibitor also effective in patients who have already…
View Post 7 min This content is machine translated The prostate is not always to blame Obstructive micturition problems in men – State of the art. The term “benign prostatic syndrome” (BPS) describes micturition symptoms associated with the prostate. The term “benign prostatic hyperplasia” (BPH), formerly frequently used to describe micturition symptoms, describes only a histological…
View Post 3 min This content is machine translated Prostate cancer risk Bald or not, varied sex life is crucial Epidemiological studies on the association between androgenetic alopecia and risk of prostate cancer are conflicting. Now it has been shown again: Male hair loss is unsuitable as a risk marker.…
View Post 7 min This content is machine translated Active surveillance as a treatment option Status quo and challenges using the example of prostate carcinoma Studies suggest that Active Surveillance is a treatment option for tumors with low risk of progression (low-risk tumors). The treatment team should work with the patient to determine treatment strategies…
View Post 2 min This content is machine translated Men and cancer Infertility as a relevant risk factor Is male infertility a harbinger of cancer? The data situation is unclear. Several studies have shown that there is a higher risk of testicular cancer, but the relationship with other…
View Post 8 min This content is machine translated Therapies in geriatric oncology. Elderly patients with prostate or colorectal cancer As the population in Switzerland ages, even more people will develop cancer at an advanced age in the future. In these patients, treatment decisions are often complex because, due to…
View Post 2 min This content is machine translated Immunosuppression in prostate cancer New therapeutic targets are being explored What is certain: The survival prognosis of metastatic castration-resistant prostate cancer (mCRPC) has improved – on average from just over one (before 2000) to almost three years [1]. Nevertheless, current…
View Post 2 min This content is machine translated Bladder Cancer Promising immunotherapy A new phase I trial with a compound targeting the immunosuppressive protein PDL1 shows promising results with a good toxicity profile. This provides a potentially new class of drugs for…
View Post 5 min This content is machine translated EMUC Congress 2014 Active surveillance and androgen deprivation in prostate cancer. At the EMUC Congress in Lisbon, two sessions highlighted diagnostic and therapeutic strategies in prostate cancer. One was the benefits and effects of Active Surveillance, and the other was a…
View Post 11 min This content is machine translated Female urinary incontinence An update for the family physician Urinary incontinence is one of the most common conditions in women. For example, the prevalence of urinary incontinence is 17% in women between 30 and 49 years of age, 23%…
View Post 7 min This content is machine translated The benign prostate syndrome Exhaust drug therapy options before surgery Benign prostatic syndrome (BPS) is one of the most common reasons for physician consultation in older men. During diagnosis, the severity of symptoms and the patient’s level of distress should…
